ACADIA Pharmaceuticals

Balance sheet: 851 million dollars of cash, cash equivalents, and investment securities at March 31, 2026; no debt on the face of the balance sheet, with operating lease liabilities the main long‑term obligations. Cash increased in 1Q26 driven by operating cash flow.

Profitability and cash flow: FY2025 GAAP revenue 1.07 billion dollars; operating cash flow 109.8 million dollars in 2025; 1Q26 operating cash flow 34.0 million dollars. Capex remains light. This yields ample liquidity to fund R&D, launches, and European efforts.